Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | BRD1 | O95696 | 1/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633323 | 0.81 | MAPT (0.58) | CA12CA9MAPTMEN1KMT2A | |
| SCHEMBL633319 | 0.78 | MAPT (0.69) | CA12CA9MAPTMEN1KMT2A | |
| SCHEMBL10138486 | 0.76 | KMT2A (0.45) | MAPTMEN1KMT2AMAPK1HTT | |
| SCHEMBL633157 | 0.76 | STAT3 (0.58) | CA12CA9MAPTMEN1KMT2A | |
| SCHEMBL633266 | 0.76 | CA12 (0.57) | CA12CA9MAPTMEN1KMT2A | |
| SCHEMBL10119718 | 0.74 | KMT2A (0.58) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL633327 | 0.74 | CA12 (0.83) | CA12CA9MAPTMEN1KMT2A | |
| SCHEMBL8752463 | 0.73 | CA12 (1.00) | CA12CA9MAPTMEN1KMT2A | |
| SCHEMBL16509495 | 0.72 | FFAR4 (0.60) | CA12CA9MEN1KMT2AMAPK1 | |
| SCHEMBL10119724 | 0.72 | CA12 (0.79) | CA12CA9MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466182-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2013-06-18 | — | — | US | claimed |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED | 2012-02-23 | — | — | US | claimed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | claimed |
| US-8466182-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466182-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED | 2012-02-23 | — | — | US | disclosed |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED | 2012-02-23 | — | — | US | disclosed |
| EP-2420494-A1 | Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8071631-B2 | An enzyme in the tryptophan degradation pathway, used to treat neurodegenerative disorders, certain cancers, drug addiction; arylsulfonamides such as 3,4-dimethoxy-N-[5-(4-chlorophenyl)-1,2,4-thiadiazole-3-yl]benzenesulfonamide | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071631-B2 | An enzyme in the tryptophan degradation pathway, used to treat neurodegenerative disorders, certain cancers, drug addiction; arylsulfonamides such as 3,4-dimethoxy-N-[5-(4-chlorophenyl)-1,2,4-thiadiazole-3-yl]benzenesulfonamide | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071631-B2 | An enzyme in the tryptophan degradation pathway, used to treat neurodegenerative disorders, certain cancers, drug addiction; arylsulfonamides such as 3,4-dimethoxy-N-[5-(4-chlorophenyl)-1,2,4-thiadiazole-3-yl]benzenesulfonamide | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2054056-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | disclosed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | disclosed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | disclosed |
| WO-2008022286-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008022286-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | KMO, KYNU, TDO2 | CA12 3442/4885CA9 3038/4885MAPT 680/4885 |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | KMO, KYNU, TDO2 | CA12 3442/4885CA9 3038/4885MAPT 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.